MCA-treated B6/J mice were randomized 30d after challenge into 6 groups of 10 mice each and interventions were initiated and continued for 60d, as indicated above. Group 7 consisted of 10 naïve mice, which received the vaccine for use as controls for monitoring p53 peptide-specific T cells. The experiment was terminated when all MCA mice had tumors that exceeded allowed tumor size limits, necrotic tumors and/or showed decreased health status mandating their removal from a study.
) indicates treatment with p53 V2 vaccine only. The experimental protocol consisted of 6 groups of 10 mice each with therapy initiated 30d post MCA challenge and either continuous intervention for 90 days or 2 segments of 45d each, as indicated above. Group 7 consisted of 10 naïve mice, which received the vaccine for use as controls for monitoring anti-wt p53 peptide-specific T cells. The experiment was terminated when all MCA mice had tumors that exceeded allowed tumor size limits, necrotic tumors and/or showed decreased health status mandating their removal from a study.
